Alterity Therapeutics (ATHE) Current Deferred Revenue (2012 - 2013)
Alterity Therapeutics (ATHE) posted Current Deferred Revenue of $30924.5 for Q4 2013, up 1.26% on a QoQ basis from $30540.3 in Q4 2013, and down 41.41% year-over-year from $52778.0 in Q4 2012.
Powered by 
Analysis
Alterity Therapeutics (ATHE) Current Deferred Revenue (2012 - 2013) Analysis & Trends
Alterity Therapeutics has reported Current Deferred Revenue for 2 years, with the latest figure at $30924.5 in Q4 2013.
- On a quarterly basis, Current Deferred Revenue fell 41.41% year-over-year to $30924.5 in Q4 2013; TTM through Dec 2013 was $30924.5, a 41.41% decrease from a year earlier, with the FY2013 full-year figure at $34240.0, down 34.74% from the prior year.
- Current Deferred Revenue was $30924.5 for Q4 2013 at Alterity Therapeutics, up from $30540.3 in the prior quarter.
- The five-year high for Current Deferred Revenue was $52779.0 in Q4 2012, with the low at $30540.3 in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Alterity Therapeutics | 72.80 Mn | 72.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | 30,924.48 |
| Oct 1, 2013 | 30,540.25 |
| Jun 30, 2013 | 33,113.35 |
| Dec 31, 2012 | 52,778.02 |
| Oct 2, 2012 | 52,778.95 |
| Jun 30, 2012 | 51,366.44 |